Loading...
•
Sep 30, 2023
UroGen Q3 2023 Earnings Report
UroGen reported strong JELMYTO® growth and progress with UGN-102 NDA submission.
Key Takeaways
UroGen Pharma reported JELMYTO® net product revenues of $20.9 million in Q3 2023, representing approximately 30% growth compared to the same period last year. The company is also preparing for a rolling NDA submission for UGN-102, planned for January 2024.
JELMYTO® net product revenues reached $20.9 million in Q3 2023, a ~30% increase year-over-year.
Agreement reached with the FDA to proceed with a rolling NDA for UGN-102, starting in January 2024.
ENVISION and ATLAS Phase 3 clinical trials met their primary endpoints in treating LG-IR-NMIBC.
Cash, cash equivalents and marketable securities totaled $153.9 million as of September 30, 2023.
UroGen
UroGen
UroGen Revenue by Segment
Revenue by Segment
JELMYTO Revenue
CapyFin.com Forward Guidance
UroGen Pharma provided full year 2023 net product revenues from JELMYTO to be in the range of $76 to $86 million.
Positive Outlook
- Full year 2023 net product revenues from JELMYTO to be in the range of $76 to $86 million.
- Full year 2023 operating expenses in the range of $135 to $145 million.
- Non-cash share-based compensation expense of $6.0 to $11.0 million, subject to market conditions.
- Full year 2023 non-cash financing expense related to the prepaid obligation to RTW Investments in the range of $21.0 to $26.0 million.
- Approximately $9.9 to $11.2 million is expected to be in cash.